Targeted Disruption of the Acid α-Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II
Open Access
- 1 July 1998
- journal article
- Published by Elsevier BV
- Vol. 273 (30), 19086-19092
- https://doi.org/10.1074/jbc.273.30.19086
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Complete correction of acid α-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscleGene Therapy, 1998
- Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.JCI Insight, 1998
- Retroviral Transfer of Acidα-Glucosidase cDNA to Enzyme-Deficient Myoblasts Results in Phenotypic Spread of the Genotypic Correction by Both Secretion and FusionHuman Gene Therapy, 1997
- Mouse models of human genetic disease: Which mouse is more like a man?BioEssays, 1996
- Animal models of human disease for gene therapy.JCI Insight, 1996
- Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients.Journal of Medical Genetics, 1995
- Genetic defects in patients with glycogenosis type II (acid maltase deficiency)Muscle & Nerve, 1995
- Glycogenosis type II (acid maltase deficiency)Muscle & Nerve, 1995
- LYSOSOMAL STORAGE DISEASESAnnual Review of Biochemistry, 1991
- Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice.JCI Insight, 1991